NASDAQ : APLM
Apollomics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 20.69 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 45.44M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 45.77M |
| Enterprise Value | 43.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 21, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 2.20M |
| Shares Outstanding | 2.20M |
| Shares Change (YoY) | +41.77% |
| Shares Change (QoQ) | +62.18% |
| Owned by Insiders (%) | 70.12% |
| Owned by Institutions (%) | 0.56% |
| Float | 534,992 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.14 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 4.84 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.96 |
| Quick Ratio | 0.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -140.48 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -1,305.37% |
| Return on Assets (ROA) | -57.61% |
| Return on Invested Capital (ROIC) | -347.45% |
| Return on Capital Employed (ROCE) | -2,353.35% |
| Weighted Average Cost of Capital (WACC) | 12.64% |
| Revenue Per Employee | $631,571 |
| Profits Per Employee | -$781,357 |
| Employee Count | 14 |
| Asset Turnover | 0.89 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 3,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.54 |
| 52-Week Price Change | +49.18% |
| 50-Day Moving Average | 23.42 |
| 200-Day Moving Average | 19.03 |
| Relative Strength Index (RSI) | 43.64 |
| Average Volume (20 Days) | 15,367 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5,398 |
| Short Previous Month | 5,730 |
| Short % of Shares Out | 0.25% |
| Short % of Float | 1.01% |
| Short Ratio (days to cover) | 0.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 8.84M |
| Gross Profit | 8.84M |
| Operating Income | -9.13M |
| Pretax Income | -10.94M |
| Net Income | -10.94M |
| EBITDA | -9.09M |
| EBIT | -9.13M |
| Loss Per Share | -$7.57 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 3.28M |
| Total Debt | 643,000 |
| Net Cash | 2.63M |
| Net Cash Per Share | $1.20 |
| Equity (Book Value) | -3.19M |
| Book Value Per Share | -1.48 |
| Working Capital | -275,000 |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.37M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 46,000 |
| Net Borrowing | -125,000 |
| Free Cash Flow | -10.37M |
| FCF Per Share | -$4.72 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -103.27% |
| Pretax Margin | -123.68% |
| Profit Margin | -123.72% |
| EBITDA Margin | -102.75% |
| EBIT Margin | -103.27% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -41.77% |
| Shareholder Yield | -41.77% |
| Earnings Yield | -36.30% |
| FCF Yield | -22.82% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 13.12% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 25, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -150.7 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |